Trial Profile
Effect of MD1003 in Progressive Multiple Sclerosis: a Randomized Double Blind Placebo Controlled Study
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 20 Jan 2022
Price :
$35
*
At a glance
- Drugs Biotin (Primary)
- Indications Multiple sclerosis
- Focus Registrational; Therapeutic Use
- Acronyms SPI2
- Sponsors MedDay Pharmaceuticals
- 20 Jan 2022 This trial has been completed in Sweden (Date of the global end of the trial : 23-Apr-2020), according to European Clinical Trials Database record.
- 01 Dec 2020 Results published in the Lancet Neurology
- 29 Oct 2020 Status changed from active, no longer recruiting to discontinued.